In this video, Dharmisha Chauhan, MPharm, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of her pharmacist and nurse-led clinic for patients with melanoma that are receiving immunotherapy. At the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Ms Chauhan highlights the importance for pharmacists to increase their skill set, in order to create a culture of advanced pharmacy practitioners in the future, and describes her experiences and roles that she plays within the clinic, to showcase the many opportunities for pharmacists.
Healthcare technologies and apps are important in supporting patients in their care, and can greatly benefit them in their treatment journey. Jonathan Moshinsky, from uMotif, London, UK, describes the advantages for both patients and healthcare professionals in using patient experience and symptoms trackers. Data collected from these activities can also act as useful resources in clinical research. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Update from the Scottish Cancer Medicines Outcome Programme
Kelly Baillie, of the NHS Greater Glasgow & Clyde, Glasgow, UK, presents the key findings from the Cancer Medicines Outcome Programme, a collaboration between NHS Greater Glasgow and Clyde and the University of Strathclyde with the aim of investigating whether medicines are as effective in real world populations, as they are in clinical trials. Looking specifically at men who received abiraterone and enzalutamide for the treatment of metastatic, castration-resistant prostate cancer, this initiative used electronic record linkage to combine the chemotherapy prescribing system with other useful patient information. At the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Ms Baillie shares the results of this retrospective study.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
The switch to biosimilar rituximab at UCH: 12 months on
At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital London of making the switch to biosimilar rituximab for the treatment of selected patients receiving treatment for follicular lymphoma. One year on, we are joined by Mr Cheesman at the 2018 BOPA Annual Symposium in Birmingham, UK, to hear how this switch has impacted patients responses and treatment costs over the past 12 months.
Content on www.vjoncology.com and www.vjhemonc.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Simon Cheesman, MRPharmS, from University College London, London, UK, describes the key outcomes from the Phase III trial (NCT01696084) looking at CPX-351, a liposomal formulation of daunorubicin and cytarabine (DA), in a patient group aged between 60-75 years old. Compared with conventional DA chemotherapy, CPX-351 showed superior efficacy in terms of overall survival, with a comparable toxicity profile. Mr Cheeseman emphasizes the fact that dose administration is simpler and more convenient for both HCPs and patients.
Content on www.vjoncology.com and www.vjhemonc.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Oncology Pharmacists play an important role in the treatment and management of patients, but how visible are they to their patients? When Oncology Pharmacist, Shereen Nabhani-Gebara, PharmD, BCOP, from Kingston University, London, UK, found herself on the other side of the table, it became clear to her that while patients and their carers receive an overwhelming amount of information regarding treatments, they have limited interaction with Oncology Pharmacists. Following this experience, Dr Nabhani-Gebara developed two surveys, one for parents of children receiving cancer treatment, and the other for Oncology Pharmacists, in order to learn more about this relationship.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Smart app to allow patients to manage their side effects independently
Managing side effects can be an overwhelming experience for oncology patients, they may be unsure of the severity of their symptoms and could be reluctant to contact their healthcare team. Shereen Nabhani-Gebara, PharmD, BCOP, from Kingston University, London, UK, and her team have developed an app which aims to target this issue. Using this app, patients can look up their symptoms and receive useful information on how to management their symptom and, where necessary, are advised to seek medical attention. Dr Nabhani-Gebara tells us about the positive effect using this app has had on the breast cancer patients so far and believes that it can be effective in other patient groups too. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
cancer-druginteractions.org: a comprehensive tool for HCPs
More than half of patients that undergo cancer treatment are estimated to have had at least one potential drug-drug interaction. Here, Jasmine Martin, MSc, of the University of Liverpool, Liverpool, UK, talks about the purpose of the Cancer Drug Interactions website as a tool to assist healthcare professionals in treating patients, while ensuring significant interactions are avoided. Speaking at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Ms Martin outlines the importance of smart apps in the healthcare setting.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
The increased use of targeted therapies in oncology has introduced a range of new side effects. Emma Foreman, BPharma (Hons) of The Royal Marsden NHS Foundation Trust, London, UK, discusses how these side effects, for example cardiological, neurological or rheumatoid side effects, have introduced the need for Oncology Pharmacists to become more knowledgeable on other specialities. Ms Foreman thinks that there is a role for groups like the British Oncology Pharmacy Association (BOPA) to produce training and educational materials to help Oncology Pharmacists bridge these knowledge gaps. This interview was recorded at BOPA Annual Symposium 2018, held in Birmingham, UK.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Non-medical prescribing: advice for those starting out
A specialist workshop on non-medical prescribing was hosted at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, Birmingham, UK. The aim of this session was to encourage open discussion around the issues and challenges faced by Oncology Pharmacists. Emma Foreman, BPharma (Hons), from the Royal Marsden NHS Foundation Trust, London, UK, shares insights from the workshop which were of help to those new to non-medical prescribing. These included finding your area of expertise, what to consider when setting up a practise and working within a multidisciplinary team. Ms Foreman also highlights the importance of networking, especially through organisations like BOPA.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
The British Oncology Pharmacy Association (BOPA) has a number of exciting educational initiatives in the pipeline for 2019. BOPA committee member, Bryn Thomas, MPharm, from The Royal Marsden NHS Foundation Trust, London, UK, tells us about the ongoing work at BOPA and their plans to organise for more networking events in the future to encourage engagement within the Oncology Pharmacist community. This video was recorded at the BOPA Annual Symposium 2018, held in Birmingham, UK.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd